Medicine's Not Going Anywhere: 3 of the Most Resilient Healthcare ETFs

The article highlights three healthcare ETFs as resilient, long-term growth vehicles: Vanguard Health Care ETF (VHT) at a 0.09% expense ratio, iShares U.S. Medical Devices ETF (IHI) at 0.38%, and Global X HealthTech ETF (HEAL) at 0.50%. It emphasizes defensive demand for medical care plus innovation in pharmaceuticals, medical devices, and digital health, with holdings such as Eli Lilly, Johnson & Johnson, Intuitive Surgical, Abbott, Oscar Health, Iqvia, and Dexcom. This is largely educational commentary rather than a market-moving catalyst.

Analysis

The common denominator here is not “healthcare is defensive,” but that the market is rewarding businesses with pricing power plus recurring utilization. That favors the large-cap compounders most exposed to procedure volumes, specialty drugs, and diagnostic workflows, while pressuring lower-quality digital health names that still depend on venture-style growth assumptions and cheap capital. The second-order effect is that any sustained rotation into healthcare can pull money away from software-like growth multiple expansion and into cash-generative care delivery and tools.

Within the basket, IQV, DXCM, ISRG, and ABT look better positioned than the broader ETF narrative suggests because their demand is tied to workflow penetration rather than pure discretionary adoption. The subtle winner is the services-and-tools layer: CROs, diagnostics, and device platforms benefit when providers seek productivity gains without adding headcount. By contrast, OSCR remains the weakest link because insurance economics are exposed to medical cost inflation and utilization spikes; if healthcare spending broadens, that is not automatically good for thin-margin managed care or consumer-facing digital insurers.

The contrarian read is that the “AI/telehealth” angle is likely overstated near term. Digitization improves distribution and monitoring, but reimbursement, clinical adoption, and regulation are slower than product cycles, so a lot of the upside can remain trapped in revenue growth without immediate margin expansion. Over 6–18 months, the real catalyst is not a tech re-rating but whether higher procedure volumes and improved throughput show up in earnings revisions; if not, the sector can underperform despite good headlines.

I would treat this as a quality-factor healthcare trade, not a broad beta trade. The opportunity is in owning the durable cash generators and fading the unprofitable promise set. The main risk is that a rapid risk-on tape compresses healthcare multiples versus cyclical growth, but the setup still looks attractive on a 3–12 month horizon if earnings revisions continue to grind higher.

Key Decisions for Investors

• Long ISRG / short OSCR for a 3-6 month pair trade: own procedure-linked compounding versus underwriting-sensitive exposure; target 15-20% relative outperformance, stop if healthcare utilization data softens materially.
• Overweight IQV and ABT on a 6-12 month horizon: both benefit from operating leverage in clinical research, diagnostics, and provider productivity; favorable risk/reward versus higher-beta digital health names.
• Add to JNJ and ABBV as defensive cash-flow anchors while healthcare sentiment is constructive; expect lower volatility and better drawdown protection than HEAL-style exposure if rates or risk appetite reverse.
• Avoid or underweight OSCR until the market sees sustained margin stabilization; upside exists if medical cost trends decelerate, but the setup is asymmetric to the downside if utilization remains elevated.
• If seeking thematic exposure, prefer VHT over HEAL for core allocation, then express digital upside with a smaller satellite position only after reimbursement/earnings inflect, not on narrative alone.